ORGANIZATION

• Opinion Reflected to Certain Degree for Comparator PMP Deduction Rule: FPMAJ
  June 12, 2020

• Impact of Off-Year Drug Re-Pricing Should Be Limited: FPMAJ
  June 12, 2020

• Eisai’s Akana Elected as New Chair of FPMAJ’s Drug Pricing Committee
  June 12, 2020

• New Special Rule for “Indication Change” Re-Pricing Significantly Lacks Predictability: FPMAJ
  June 12, 2020

• 3 Healthcare Organizations Prod Govt to Forgo FY2020 Drug Price Survey
  June 11, 2020

• Postpone Off-Year Drug Re-Pricing Until 2023 or Beyond: JPMA
  June 11, 2020

• Daiichi Sankyo CEO Manabe Set to Gain Lobbying Experience as FPMAJ Vice Chair, Chairman Seat Eyed for 2021
  June 10, 2020

• Japan Pharma Trade Group Nudges Govt to Postpone Off-Year Re-Pricing
  June 8, 2020

• Patient Advocacy Group Urges MLHW to Increase Funding for Pancreatic Cancer Research
  June 8, 2020

• API/Intermediate Imports from India Still Stalled, Traders’ Group Calls for Govt Schemes
  June 4, 2020

• JGA Chief Sawai to Stay in His Post, Deputy Chief Tamura Stepping Down
  June 4, 2020

• JPMA Reprimands Torii, Nippon Chemiphar over Price-Fixing
  May 29, 2020

• JPMA to Compile Proposal for Measures against Infectious Diseases: Chief
  May 29, 2020

• JPWA Resolution Urges Govt to Revisit Off-Year Drug Re-Pricing
  May 29, 2020

• Generic/Biosimilar Society Calls on MHLW to Ensure Stable API Supply
  May 26, 2020

• Japan Pharmacist Group Renews Opposition to Off-Year Re-Pricing in FY2021
  May 22, 2020

• Pneumococcal Vaccination Rate in Children Falls Sharply amid COVID-19 Pandemic: Survey
  May 21, 2020

• JCHO Hospitals to Switch from Joint to Separate Bidding for Drug Purchases after Bid-Rigging Scandal
  May 21, 2020

• Don’t Give Hasty COVID-19 Nod for Existing Drugs, Follow Int’l Rules for Avigan Approval: JMA
  May 21, 2020

• Hodanren Criticizes Zolgensma’s High NHI Price as “Result of a Money Game”
  May 18, 2020

ページ

• « 先頭
• ‹ Prev
• …
• 29
• 30
• 31
• 32
• 33
• 34
• 35
• 36
• 37
• …
• Next ›
• 最終 »